drugset
drugset / Trial / NCT07266155

Efficacy, Safety, and Pharmacokinetics of LP-005 Injection in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT07266155 ↗

Phase 2 Not yet recruiting 30 enrolled Longbio Pharma
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is an extension study for patients who have completed a prior P10-LP005-02 clinical study. The aim of this study is to evaluate the long-term safety, efficacy, and pharmacokinetics of LP-005 injection in adult patients with paroxysmal nocturnal hemoglobinuria (PNH).

Timeline

Start
2025-12-05
Primary completion
2027-12-30
Completion
2028-05-01

Drugs

EvaluationDrugModalityDoseRoute
Subject LP-005 Protein / enzyme biologic 1200 mg Intravenous
Subject LP-005 Protein / enzyme biologic 1500 mg Intravenous

Indications

paroxysmal nocturnal hemoglobinuria